Company: SMNR
Filing Date: 2025-08-08
Form Type: S-4/A
Source: 0001193125-25-177097
Chunk: 578

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-08
Form: S-4/A
Chunk 578
---
 |   |     |             |      |   |     |              |          |   |     |    |     |              | 234,126,025 |   |     |             |          |   |     |    |     |               | 234,115,090 |   |     |             |          |   |     |    |     |               | 234,104,155 |   |     |             |          |   |     |    |     |             | 234,093,220 |   |     |             |          |   |     |    |     |             | 234,082,286 |   |
| Net loss per share — New Semnur, basic and diluted                                                                        |     |              |           |   |     |                  |             |   |     |             |      |   |     |              |          |   |     |    |     |              |       (2.52 | ) |     |             |          |   |     |    |     |               |       (2.52 | ) |     |             |          |   |     |    |     |               |       (2.52 | ) |     |             |          |   |     |    |     |             |       (2.52 | ) |     |             |          |   |     |    |     |             |       (2.52 | ) |

350

<div align='center'>**NOTES TO THE UNAUDITED PRO FORMA CONDENSED FINANCIAL INFORMATION**</div>

**Note 1 – Description of the Business Combination

Denali is a blank check company incorporated in the Cayman Islands on January 5, 2022. Denali was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities.

As of March 31, 2025, Denali had not yet commenced operations. All activity for the period from January 5, 2022 (inception) through March 31, 2025 relates to Denali’s formation, organizational activities, activities necessary to prepare for and complete the IPO, identifying a target company for a business combination, and activities in connection with an initial business combination, including with respect to the Business Combination.

Semnur is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative non-opioid pain management